GENE ONLINE|News &
Opinion
Blog

2022-05-11| Partnerships

NVIDIA & Singular Genomics Team Up to Boost Next-Gen Sequencing Capabilities

by Fujie Tham
Share To

Singular Genomics Systems and NVIDIA are teaming up to validate and optimize the G4 Sequencing Platform with NVIDIA Clara Parabricks for accelerated bioinformatics applications. 

The G4 sequencer is Singular Genomics’ first benchtop sequencing platform, utilizing its exclusive ​​4-color sequencing by synthesis (SBS) chemistry and equipped with NVIDIA RTX A6000 for AI-enabled basecalling. This collaboration will enable Clara Parabricks access for the Singular’s G4 sequencing system, enabling accelerated bioinformatics applications in whole-genome, cancer, RNA sequencing, and targeted gene screening, coupled with Amazon Cloud functionalities.

As demand for sequencing increases, the volume of data generated grows exponentially, algorithms and workflows used for data analysis are known to be the primary bottleneck. NVIDIA’s Clara Parabricks addresses this issue with an accelerated and scalable suite optimized for genomic analysis on graphics processing units (GPUs). This collaboration further extends NVIDIA’s technology to downstream genomics workflow. 

“Time to results is crucial across most NGS applications, and we believe that Clara Parabricks and NVIDIA’s best-in-class GPU architecture combined with the speed and flexibility of the G4 Sequencing Platform is a natural fit,” said George Vacek, NVIDIA Global Director of Genomics Alliances.

Related article: Cancer Cells Build Nano-Highways to Hijack Mitochondria from Immune Cells

 

Singular Genomics’ First Commercial Sequencing Platform

 

Aiming to compete with Illumina in the benchtop sequencer market, the San Diego-based company went public in May 2021 and launched its first commercial sequencer later that year. Singular Genomics has deals to make sample library preparation kits from Twist Bioscience, New England BioLabs, and Dovetail compatible with its platform, integrating established workflows into the G4.

Wasting no time to support its first product, the company later secured a partnership with Broad Institute to integrate the Terra platform developed jointly with Microsoft and Alphabet into G4, further ameliorating its cloud data analysis abilities.

The G4x4, a four-instrument configuration designed to address customers with high sequencing output demands, is scheduled for launch before the end of 2022. The company did not disclose any financial and other terms of the NVIDIA agreement.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Why NVIDIA’s CEO Huang Said AI Fostering Life Science:Highlighting GPU’s Applications in Biotech
2024-02-23
JPM 2024: Generative AI Reshapes Medical Paradigms, Transforming the Past
2024-01-15
R&D
Revolutionary Sequencing Technique for Cancer Signature Detection
2023-07-11
LATEST
Pfizer’s Q1 2024 Revenue Declines, Offset by Strong Performance of Non-COVID-19 Products
2024-05-03
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
Taiwan Breakthrough: Next-Generation Sequencing Now Covered in Health Insurance, Benefitting 20,000 Cancer Patients Annually
2024-05-02
CellTech Accelerator and Cyto-Facto Inc. Forge Strategic Partnership to Advance CGT Industry Growth
2024-04-29
Kaiser’s Data Breach: 13.4 Million Affected in Healthcare Conglomerates Privacy Crisis
2024-04-26
EVENT
Scroll to Top